Cargando…
The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow
BACKGROUND: Slow coronary flow (SCF) is an angiographic finding characterized with delayed opacification of epicardial coronary arteries without obstructive coronary disease. Urotensin II (UII) is an important vascular peptide, which has an important role in hypertension, coronary artery disease, an...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Akadémiai Kiadó
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5283774/ https://www.ncbi.nlm.nih.gov/pubmed/28180005 http://dx.doi.org/10.1556/1646.8.2016.4.1 |
_version_ | 1782503548317073408 |
---|---|
author | Şatıroğlu, Ömer Durakoğlugil, Murtaza Emre Çetin, Mustafa Çiçek, Yüksel Erdoğan, Turan Duman, Hakan |
author_facet | Şatıroğlu, Ömer Durakoğlugil, Murtaza Emre Çetin, Mustafa Çiçek, Yüksel Erdoğan, Turan Duman, Hakan |
author_sort | Şatıroğlu, Ömer |
collection | PubMed |
description | BACKGROUND: Slow coronary flow (SCF) is an angiographic finding characterized with delayed opacification of epicardial coronary arteries without obstructive coronary disease. Urotensin II (UII) is an important vascular peptide, which has an important role in hypertension, coronary artery disease, and vascular remodeling in addition to potent vasoconstrictor effect. OBJECTIVES: We investigated UII levels, hypertension, and other atherosclerotic risk factors in patients with SCF, a variety of coronary artery disease. METHODS: We enrolled 14 patients with SCF and 29 subjects with normal coronary arteries without SCF. We compared the UII levels and the atherosclerotic risk factors between patients with SCF and control subjects with normal coronary flow. RESULTS: UII concentrations were significantly higher in patients with SCF compared to controls (711.0 ± 19.4 vs. 701.5 ± 27.2 ng/mL, p = 0.006). We detected a positive correlation between SCF and age (r = 0.476, p = 0.001), BMI (r = 0.404, p = .002), UII concentrations (r = 0.422, p = 0.006), and hypertension (r = 0.594, p = 0.001). CONCLUSION: We identified increased UII levels in patients with SCF. We think that UII concentrations may be informative on SCF pathogenesis due to relationship with inflammation, atherosclerosis, and vascular remodeling. |
format | Online Article Text |
id | pubmed-5283774 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Akadémiai Kiadó |
record_format | MEDLINE/PubMed |
spelling | pubmed-52837742017-02-08 The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow Şatıroğlu, Ömer Durakoğlugil, Murtaza Emre Çetin, Mustafa Çiçek, Yüksel Erdoğan, Turan Duman, Hakan Interv Med Appl Sci Original Paper BACKGROUND: Slow coronary flow (SCF) is an angiographic finding characterized with delayed opacification of epicardial coronary arteries without obstructive coronary disease. Urotensin II (UII) is an important vascular peptide, which has an important role in hypertension, coronary artery disease, and vascular remodeling in addition to potent vasoconstrictor effect. OBJECTIVES: We investigated UII levels, hypertension, and other atherosclerotic risk factors in patients with SCF, a variety of coronary artery disease. METHODS: We enrolled 14 patients with SCF and 29 subjects with normal coronary arteries without SCF. We compared the UII levels and the atherosclerotic risk factors between patients with SCF and control subjects with normal coronary flow. RESULTS: UII concentrations were significantly higher in patients with SCF compared to controls (711.0 ± 19.4 vs. 701.5 ± 27.2 ng/mL, p = 0.006). We detected a positive correlation between SCF and age (r = 0.476, p = 0.001), BMI (r = 0.404, p = .002), UII concentrations (r = 0.422, p = 0.006), and hypertension (r = 0.594, p = 0.001). CONCLUSION: We identified increased UII levels in patients with SCF. We think that UII concentrations may be informative on SCF pathogenesis due to relationship with inflammation, atherosclerosis, and vascular remodeling. Akadémiai Kiadó 2016-12-29 2016-12 /pmc/articles/PMC5283774/ /pubmed/28180005 http://dx.doi.org/10.1556/1646.8.2016.4.1 Text en © 2016 The Author(s) http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium for non-commercial purposes, provided the original author and source are credited. |
spellingShingle | Original Paper Şatıroğlu, Ömer Durakoğlugil, Murtaza Emre Çetin, Mustafa Çiçek, Yüksel Erdoğan, Turan Duman, Hakan The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow |
title | The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow |
title_full | The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow |
title_fullStr | The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow |
title_full_unstemmed | The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow |
title_short | The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow |
title_sort | role of urotensin ii and atherosclerotic risk factors in patients with slow coronary flow |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5283774/ https://www.ncbi.nlm.nih.gov/pubmed/28180005 http://dx.doi.org/10.1556/1646.8.2016.4.1 |
work_keys_str_mv | AT satırogluomer theroleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow AT durakoglugilmurtazaemre theroleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow AT cetinmustafa theroleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow AT cicekyuksel theroleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow AT erdoganturan theroleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow AT dumanhakan theroleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow AT satırogluomer roleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow AT durakoglugilmurtazaemre roleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow AT cetinmustafa roleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow AT cicekyuksel roleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow AT erdoganturan roleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow AT dumanhakan roleofurotensiniiandatheroscleroticriskfactorsinpatientswithslowcoronaryflow |